Loncastuximab Tesirine

adc

Identifier: CI-DRUG-00000767
Entity page: /drug/loncastuximab-tesirine ↗
Edges: 58

Neighbours: 17 cancers1 genes10 trials1 approvals
Drawn: 29 of 29 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Loncastuximab Tesirine approved for …APPROVED_FOR4 of 3
→ approved for	High Grade B-Cell Lymphomahematologic_malignancy	supports	FDA ORIG	High Grade B-Cell Lymphoma	1	Regulatory	openfda	graph →
→ approved for	B-Cell Malignant Neoplasmcancer_family	supports	mesh_therapeutic_area

Loncastuximab Tesirine targets …TARGETS1 of 1
→ targets	CD19	—	BINDING AGENT	—	1	Curated	chembl	graph →

Loncastuximab Tesirine targets …TARGETS1 of 1

→ targets

CD19

—

BINDING AGENT

—

Curated

Loncastuximab Tesirine investigated for …INVESTIGATED_FOR9 of 9
→ investigated for	Neoplasmcancer_family	unknown	4	Neoplasm	1	Curated	chembl	graph →
→ investigated for	B-Cell Malignant Neoplasmcancer_family	unknown	4	B-Cell Malignant Neoplasm	1	Curated	chembl	graph →
→ investigated for	Mantle Cell Lymphomahematologic_malignancy	unknown	2	Mantle Cell Lymphoma	1	Curated	chembl	graph →
→ investigated for	Non-Hodgkin Lymphomahematologic_malignancy	unknown	2	Non-Hodgkin Lymphoma	1	Curated	chembl	graph →
→ investigated for	Waldenstrom Macroglobulinemiahematologic_malignancy	unknown	2	Waldenstrom Macroglobulinemia	1	Curated	chembl	graph →
→ investigated for	Follicular Lymphomahematologic_malignancy	unknown	2	Follicular Lymphoma	1	Curated	chembl	graph →
→ investigated for	Chronic Lymphocytic Leukemiahematologic_malignancy	unknown	1	Chronic Lymphocytic Leukemia	1	Curated	chembl	graph →
→ investigated for	Burkitt Lymphomahematologic_malignancy	unknown	1	Burkitt Lymphoma	1	Curated	chembl	graph →
→ investigated for	Acute Lymphoblastic Leukemiahematologic_malignancy	unknown	1	Acute Lymphoblastic Leukemia	1	Curated	chembl	graph →

Loncastuximab Tesirine investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 20show all (up to 200)
→ investigated in trials for	Diffuse Large B-Cell Lymphoma 10 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Diffuse Large B-Cell Lymphoma	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Follicular Lymphomahematologic_malignancy 4 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Follicular Lymphoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	B-Cell Non-Hodgkin Lymphoma 3 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	B-Cell Non-Hodgkin Lymphoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	High Grade B-Cell Lymphomahematologic_malignancy 3 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	High Grade B-Cell Lymphoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Mantle Cell Lymphomahematologic_malignancy 3 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Mantle Cell Lymphoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Non-Hodgkin Lymphomahematologic_malignancy 3 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Non-Hodgkin Lymphoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Primary Mediastinal Large B-Cell Lymphoma 3 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Primary Mediastinal Large B-Cell Lymphoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements 2 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Lymphoma 2 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lymphoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Waldenstrom Macroglobulinemiahematologic_malignancy 2 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Waldenstrom Macroglobulinemia	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Acute Lymphoblastic Leukemiahematologic_malignancy 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Acute Lymphoblastic Leukemia	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Burkitt Lymphomahematologic_malignancy 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Burkitt Lymphoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Chronic Lymphocytic Leukemiahematologic_malignancy 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Chronic Lymphocytic Leukemia	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Double-Expressor Lymphoma 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Double-Expressor Lymphoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Grade 3b Follicular Lymphoma 1 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Grade 3b Follicular Lymphoma	1	Observed	clinicaltrials	graph →

Loncastuximab Tesirine studied in …STUDIED_INderived10 of 25show all (up to 200)
→ studied in	NCT05600686Phase 2 · active not recruiting Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma · 25 trials list this drug (13 active)	—	—	Double-Expressor Lymphoma,High Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements,High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements+1	1	Observed	clinicaltrials	graph →
→ studied in	NCT06788964Phase 2 · recruiting Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL) · 25 trials list this drug (13 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT07308132Phase 1 · recruiting A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies · 25 trials list this drug (13 active)	—	—	Non-Hodgkin Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05660395Phase 1 · terminated A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10) · 25 trials list this drug (13 active)	—	—	Diffuse Large B-Cell Lymphoma,High Grade B-Cell Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04970901Phase 1 · active not recruiting A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) · 25 trials list this drug (13 active)	—	—	B-Cell Non-Hodgkin Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05464719Phase 2 · recruiting A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy · 25 trials list this drug (13 active)	—	—	Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05672251Phase 2 · recruiting Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma · 25 trials list this drug (13 active)	—	—	Diffuse Large B-Cell Lymphoma,Primary Mediastinal Large B-Cell Lymphoma,Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma+2	1	Observed	clinicaltrials	graph →
→ studied in	NCT05453396Phase 2 · terminated Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies · 25 trials list this drug (13 active)	—	—	B-Cell Non-Hodgkin Lymphoma,Diffuse Large B-Cell Lymphoma,Follicular Lymphoma+1	1	Observed	clinicaltrials	graph →
→ studied in	NCT05053659Phase 1 · active not recruiting Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma · 25 trials list this drug (13 active)	—	—	Non-Hodgkin Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05190705Phase 2 · active not recruiting Loncastuximab Tesirine in WM · 25 trials list this drug (13 active)	—	—	Waldenstrom Macroglobulinemia	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Paths